

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 December 2011 (01.12.2011)

(10) International Publication Number
WO 2011/149822 A1

(51) International Patent Classification:
C07F 5/02 (2006.01)

(21) International Application Number:
PCT/US2011/037525

(22) International Filing Date:
23 May 2011 (23.05.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/348,384 26 May 2010 (26.05.2010) US

(71) Applicant (for all designated States except US):
BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Binger Strasse 173, 55216 Ingelheim am Rhein (DE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **TAN, Zhulin** [US/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, Connecticut 06877-0368 (US).


(74) Agents: **MORRIS, Michael P.** et al.; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: 2-OXO-1,2-DIHYDROPYRIDIN-4-YLBORONIC ACID DERIVATIVES



(57) Abstract: The present invention relates to a compound of formula (I) wherein R^1 , R^2 and n are as defined herein. The invention also relates to processes for making the compounds of formula (I) and methods of using the compounds of formula (I) as reagents in organic synthesis.

WO 2011/149822 A1

Published:

— *with international search report (Art. 21(3))*

2-OXO-1,2-DIHYDROPYRIDIN-4-YLBORONIC ACID DERIVATIVES

FIELD OF THE INVENTION

The invention relates to 2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives,
5 methods of making these compounds, and their use in chemical processes.

BACKGROUND OF THE INVENTION

The Suzuki coupling reaction provides an efficient process for joining arenes (aryls
and/or heteroaryls) in the presence of a palladium catalyst (see, e.g., N. Miyaura et al.,
10 *Synthetic Communications* 11: 7, 51- 519 (1981); and N. Miyaura et al. *Chem. Rev.* 95:
2457-2483 (1995). In the Suzuki reaction, a haloarene is reacted with an areneboronic acid
in the presence of Pd catalyst and base to form a biarene product. The reaction can also be
carried out using areneboronic esters instead of areneborate acids.


WO2009074812 describes a Suzuki couplings using an areneborate ester, that is, 1-
15 methyl-4-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl) pyridin-2(1 H)-one.
WO2009/017664, WO2009/134400, WO2009/017671, and WO2010/011314 also describe
Suzuki couplings using areneborate esters including pyridylborate esters to prepare
compounds useful for treating metabolic disorders such as diabetes.

WO2009/017664, WO2009/134400, WO2009/017671, and WO2010/011314
20 describe Suzuki coupling reactions using a reagent of formula $(HO)_2B-Cy^2$, where Cy is
described as aryl, heteroaryl, cycloalkyl or heterocyclyl. The references also describe
compounds where Cy is pyridine and oxo-pyridine.

However, Applicants are unaware of any 2-oxo-1,2-dihydropyridin-4-ylboronic
acid derivative where the pyridine nitrogen atom is substituted by an alkyl or cycloalkyl.
25 Such compounds are useful for making compounds in which a 2-oxo-1,2-dihydropyridine
derivative is coupled to an aryl or heteroaryl ring at the 4-position of the pyridine.

BRIEF SUMMARY OF THE INVENTION

In its broadest embodiment the invention relates to 1-alkyl- and 1-cycloalkyl-2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives of formula (I):



5

wherein:

n is 0, 1, 2 or 3;

R¹ is -(C₁-C₆)alkyl or -(C₃-C₆)cycloalkyl; wherein said -(C₁-C₆)alkyl and -(C₃-C₆)cycloalkyl may be optionally substituted with one to three groups independently
10 selected from -(C₁-C₆)alkyl, -O(C₁-C₆)alkyl, halo, -NH₂, -NH(C₁-C₆)alkyl, -N((C₁-C₆)alkyl)₂, and -CN; and

each R² is independently selected from -(C₁-C₆)alkyl, -O(C₁-C₆)alkyl, -(C₃-C₆)cycloalkyl, halo, -NH₂, -NH(C₁-C₆)alkyl, -N((C₁-C₆)alkyl)₂, and -CN.

In one embodiment, the invention relates to a compound of formula (I) wherein R¹
15 is -(C₁-C₆)alkyl.

In another embodiment, the invention relates to a compound of formula (I) wherein R¹ is methyl.

In one embodiment, the invention relates to a compound of formula (I) wherein R¹ is -(C₃-C₆)cycloalkyl.

20 In another embodiment, the invention relates to a compound of formula (I) wherein R¹ is cyclopropyl.

In another embodiment, the invention relates to any of the preceding embodiments wherein n is 0.

In another embodiment, the invention relates to a compound of formula (I) wherein
25 R¹ is methyl and n is 0.

In another embodiment, the invention relates to a compound of formula (I) wherein R^1 is cyclopropyl and n is 0.

The invention also relates to methods of making the compounds of formula (I) and the use of compounds of formula (I) as reagents in chemical synthesis, e.g., in Suzuki
5 couplings.

DETAILED DESCRIPTION OF THE INVENTION

The term “-(C₁-C₆)alkyl” refers to branched and unbranched alkyl groups having from 1 to 6 carbon atoms. Examples of -(C₁-C₆)alkyls include methyl, ethyl, n-propyl,
10 isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentane, iso-pentyl, neopentyl, n-hexane, iso-hexanes (e.g., 2-methylpentyl, 3-methylpentyl, 2,3-dimethylbutyl, and 2,2-dimethylbutyl). It will be understood that any chemically feasible carbon atom of the -(C₁-C₆)alkyl group can be the point of attachment to another group or moiety.

The term “-(C₃-C₆)cycloalkyl” refers to a nonaromatic 3- to 6-membered
15 monocyclic carbocyclic radical. Examples of “-(C₃-C₆)cycloalkyls include cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl and cyclohexyl.

The term “C₆₋₁₀ aryl” refers to aromatic hydrocarbon rings containing from six to ten carbon ring atoms. The term C₆₋₁₀ aryl includes monocyclic rings and bicyclic rings where at least one of the rings is aromatic. Non-limiting examples of C₆₋₁₀ aryls include
20 phenyl, indanyl, indenyl, benzocyclobutanyl, dihydronaphthyl, tetrahydronaphthyl, naphthyl, benzocycloheptanyl and benzocycloheptenyl.

The term “5 to 11-membered heteroaryl” refers to an aromatic 5 to 6-membered monocyclic heteroaryl or an aromatic 7 to 11-membered heteroaryl bicyclic ring where at least one of the rings is aromatic, wherein the heteroaryl ring contains 1-4 heteroatoms
25 such as N, O and S. Non-limiting examples of 5 to 6-membered monocyclic heteroaryl rings include furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, pyrazolyl, pyrrolyl, imidazolyl, tetrazolyl, triazolyl, thienyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, and purinyl. Non-limiting examples of 7 to 11-membered heteroaryl bicyclic heteroaryl rings include benzimidazolyl, quinolinyl, dihydro-2H-quinolinyl,

isoquinoliny, quinazoliny, indazolyl, thieno[2,3-d]pyrimidiny, indolyl, isoindolyl, benzofuranyl, benzopyranyl, benzodioxolyl, benzoxazolyl and benzothiazolyl.


The term “arene” refers to a C₆₋₁₀ aryl or 5 to 11-membered heteroaryl.

The terms “haloarene” and “trifluoromethanesulfonyloxyarene” refer to a C₆₋₁₀ aryl or 5 to 11-membered heteroaryl containing at least one halogen (haloarene) or trifluoromethanesulfonyloxyarene (trifluoromethanesulfonyloxyarene) bonded to an arene carbon ring atom. It will be understood that the haloarene or trifluoromethanesulfonyloxyarene may be a moiety that is part of a larger molecule such as described in WO2009/017664, WO2009/134400, WO2009/017671, and WO2010/011314, the content of each of the foregoing being incorporated by reference in its entirety.

The term “halo” or “halogen” refers to fluoro, chloro, bromo or iodo.

As noted above, the invention also relates to compounds of formula (I) and methods of making the compounds of formula (I). A nonlimiting method of making the compounds of formula (I) is depicted below in Scheme 1.

Scheme 1



Accordingly, in one embodiment, the invention relates to a method of making the compounds of formula (I) as depicted in Scheme 1 comprising:

20 allowing a compound of formula (II) to react with a Grignard reagent to form a first intermediate (“Intermediate 1”);

allowing the first intermediate to react with an alkylborate to form a second intermediate (“Intermediate 2”);

and hydrolyzing the second intermediate (“the hydrolyzing step”) to provide the compound of formula (I); wherein

25 R¹, R² and n are as defined above for the compound of formula (I);

R^3 and R^4 are each independently a $-(C_1-C_6)$ alkyl;

L is a leaving group selected from halo and trifluoromethanesulfonyloxy; and

X is a chloro, bromo, or iodo.

In one embodiment, the invention relates to a method of making the compound of
5 formula (I) in the embodiment described above, wherein L is bromo.

In another embodiment, the invention relates to a method of making the compound
of formula (I) in any of the embodiments described above, wherein n is 0.

In another embodiment, the invention relates to a method of making the compound
of formula (I) in any of the embodiments described above, wherein R^1 is methyl or
10 cyclopropyl.

In another embodiment, the invention relates to a method of making the compound
of formula (I) as described in the broadest embodiment above, wherein L is bromo or
chloro; n is 0, and R^1 is methyl.

In another embodiment, the invention relates to a method of making the compound
15 of formula (I) as described in the broadest embodiment above, wherein L is bromo or
chloro; n is 0, and R^1 is cyclopropyl.

In another embodiment, the invention relates to a method of making the compound
of formula (I) as described in all the embodiments above, wherein R^3 is a branch-chain
20 $-(C_1-C_6)$ alkyl.

In another embodiment, the invention relates to a method of making the compound
of formula (I) as described in all the embodiments above, wherein R^3 is isopropyl.

In another embodiment, the invention relates to a method of making the compound
of formula (I) as described in all the embodiments above, wherein R^4 is a straight-chain
25 $-(C_1-C_6)$ alkyl.

In another embodiment, the invention relates to a method of making the compound
of formula (I) as described in all the embodiments above, wherein R^4 is methyl.

As depicted in Scheme 1, reaction of the Grignard reagent with the compound of
formula (I) forms Intermediate 1. The Grignard reaction step used to form Intermediate 1
is carried out under anhydrous conditions in an ethereal solvent such as, e.g., diethyl ether,
30 diisopropyl ether, methyl t-butyl ether, tetrahydrofuran (THF), dioxane, and combinations
thereof. A preferred solvent for the Grignard reaction step is tetrahydrofuran.

Nonlimiting examples of useful Grignard reagents include alkyl magnesium halides, e.g., isopropylmagnesium chloride. The reaction with the Grignard reagent is carried out for a time and at a temperature sufficient to allow substantially all of the Grignard reagent to react with the compound of formula (I). In one embodiment, a suitable
5 temperature is from about -30°C to about 50°C; in another embodiment, from about -30°C to about 0°C; and in another embodiment, from about -25°C to about 0°C.

In one embodiment, a suitable time for reacting the Grignard reagent with the compound of formula (I) is from about 0.25 hours to about 48 hours; in another embodiment, from about 1 hour to about 24 hours; and in another embodiment, from about
10 1 hour to about 12 hours. It will be understood that the above reaction times also includes the time required to contact the Grignard reagent with compound of formula (I).

The reaction of Intermediate 1 with the alkylborate is typically carried out by adding the alkylborate portion-wise to the first intermediate. The alkylborate can be added neat (i.e., without further dissolution in a solvent) or as a solution. When used as a
15 solution, the solvent is typically the same solvent as used during reaction of the Grignard reagent with the compound of formula (II) (e.g., an etheral solvent).

The reaction of Intermediate 1 with the alkylborate is carried out for a time and at a temperature sufficient to allow substantially all of Intermediate 1 to react with the alkyl borate. In one embodiment, a suitable temperature is from about -30°C to about 50°C; in
20 another embodiment, from about -30°C to about 0°C; and in another embodiment, from about -25°C to about 0°C.

In one embodiment, a suitable time for reacting the alkyl borate with Intermediate 1 is from about 0.25 hours to about 48 hours; in another embodiment, from about 0.5 hours to about 24 hours; and in another embodiment, from about 0.5 hours to about 12 hours. It
25 will be understood that the above reaction times also includes the time required to contact the alkyl borate with Intermediate 1.

Intermediate 2 is then hydrolyzed (“the hydrolysis step”) under conditions sufficient to convert Intermediate 2 into the compound of formula (I). The hydrolysis step can be carried out under acidic, neutral or basic conditions. Typically, the hydrolysis step
30 is carried out under acidic conditions at a temperature of from about 0°C to about 50°C; more typically at a temperature of from about 0°C to about 30°C.


After hydrolysis the compound of formula (I) is separated from the reaction mixture, purified, and dried using methods known in the art. For example, when the compound of formula (I) formed in the hydrolysis step is a solid, then the solid can be separated from the liquid phase by filtration or decantation. The solids can then be washed with a suitable solvent and dried. If desired, additional compound of formula (I) may be recovered from the liquid phase and/or solvent washes.

The compound of formula (II) is commercially available or can be made by methods known in the art (see, e.g., WO2010043396, WO2010025890, WO2010010157, WO2009134400, WO2009074812, WO2009033703, WO2009033704, WO2008107479, WO2007104783, WO2005007644, WO2006017443, and references cited therein).

As noted above, the compounds of formula (I) are useful reagents in Suzuki coupling reactions. For example, the compound of formula (I) can be reacted with a haloarene or trifluoromethanesulfonyloxyarene to form the corresponding pyridin-4-yl-2-oxo of formula (IV) as depicted below in Scheme 2.

15

Scheme 2



As depicted in Scheme 2, the compound of formula (I) is reacted with a compound of formula (III) which is an arene substituted with a leaving group L. (The arene ring shown in Scheme 2 is depicted as 6-membered ring A for clarity.) The reaction is carried out in the presence of a palladium catalyst (e.g., PdCl₂(dppf) and base (e.g., Na₂CO₃) to provide the compound of formula (IV).

The leaving group (L) depicted in the compound of formula (III) is a group that can be displaced by the boric acid moiety of the compound of formula (I). Nonlimiting

examples of leaving groups (L) include halo (chloro, bromo, or iodo) and trifluoromethanesulfonyloxy. In a preferred embodiment, L is bromo or chloro.

In one embodiment, the compound of formula (III) is a haloarene or trifluoromethanesulfonyloxyarene.

5 In a preferred embodiment, the compound of formula (III) is a haloarene or trifluoromethanesulfonyloxyarene as disclosed in WO2009/017664, WO2009/134400, WO2009/017671, and WO2010/011314.

Nonlimiting examples of palladium catalysts useful for carrying out the coupling reaction depicted in Scheme 2 include

10 [1,1'-bis(diphenylphosphino)ferrrocene]dichloropalladium(II), tetrakis(triphenylphosphine)palladium(0) ($\text{Pd}(\text{Ph}_3)_4$), palladium acetate ($\text{Pd}(\text{OAc})_2$), tris(dibenzylideneacetone)dipalladium(0), palladium on charcoal, and combinations thereof.

In one embodiment, the invention relates to a method of making a compound of formula (IV) as depicted in Scheme 2 above comprising:

15 allowing a compound of formula (III) to react with a compound of formula (I) in the presence of a palladium catalyst and base.

In one embodiment, the invention relates to a method of making the compound of formula (IV) as described in the embodiment above, wherein L is bromo or chloro.

20 In another embodiment, the invention relates to a method of making the compound of formula (IV) as described in any of the embodiments above, wherein n is 0.

In another embodiment, the invention relates to a method of making the compound of formula (IV) as described in any of the embodiments above, wherein R^1 is methyl or cycloalkyl.

25 In another embodiment, the invention relates to a method of making the compound of formula (IV) as described in any of the embodiments above, wherein the palladium catalyst is [1,1'-bis(diphenylphosphino)ferrrocene]dichloropalladium(II), complex with dichloromethane.

In another embodiment, the invention relates to a method of making the compound of formula (IV) as described in any of the embodiments above, wherein the compound of

30

formula (III) is (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one, or a hydrate thereof.

In another embodiment, the invention relates to a method of making the compound of formula (IV) as described in any of the embodiments above, wherein the compound of formula (III) is (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one is a monohydrate.

In another embodiment, the invention relates to a method of making the compound of formula (IV) as described as described second embodiment immediately above, wherein the compound of formula (III) is (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one in the form of a nonsolvate.

Examples

The following HPLC conditions are used to determine the purity of Compound **1** prepared in Example 1:

Column: Halo C18 (MAC-MOD Analytical, Inc. No. 92814-702, s/n AH072246).
4.6 x 150 mm. Particle size 2.7 μm .

Mobile phase A: water with 0.05%(v/v) phosphoric acid.

Mobile phase B: acetonitrile with 0.05%(v/v) phosphoric acid.

Gradient: 5% mobile phase B to 95% mobile phase B in 7 min; held at 95% mobile phase B for 3 min.

Runtime: 10 minutes with a post run of 2 min.

Flow rate: 1.20 mL/min.

Temperature: 25°C.

Injection: 2.0 μl .


UV detector: 220 nm, bandwidth 8 nm; ref 500 nm, bandwidth 100 nm.

Example 1

Synthesis of 1-methyl-2-oxo-1,2-dihydropyridin-4-ylboronic acid (**1**). Compound **1** is prepared using the procedure depicted in Scheme 3 and described below.

30

Scheme 3



Step 1. A solution of isopropylmagnesium chloride (175 mL, 1.85 M in THF, 0.32 mol, 1.54 eq.) is charged to a 500-mL jacketed reactor under nitrogen atmosphere with mechanical agitation. The contents of the reactor are cooled to -18°C and treated with a solution of 4-bromo-1-methylpyridine-2(1H)-one (40.0 g, 0.21 mol, 1.00 eq.) over about 1 hour. The rate of addition is controlled to maintain a reaction temperature of no higher than -15°C . The contents of the reactor are warmed to -10°C , mixed for 1 hour, and warmed to 20°C .

Step 2. The contents of the reactor from Step 1 are cooled to -20°C and treated with neat trimethylborate (38 mL, 0.36 mol, 1.62 eq.) at a rate sufficiently slow (approximately 1 hour) to keep the batch temperature at or below -15°C . The contents of the reactor are then warmed to -10°C , mixed for 1 hour, and warmed to 20°C .

Step 3. Hydrochloric acid (140 mL, 2.56 N, 0.36 mol, 1.70 eq.) is cooled to about 5°C and treated with the reaction mixture from Step 2. The rate of addition is slow enough to maintain a reaction temperature of less than 25°C . The contents of the reactor are then mixed at 20°C for 6 hours. The resultant solids are collected by filtration, washed with isopropyl acetate (50 mL), and dried under reduced pressure at 21°C to provide a first crop of **1** as a white crystalline solid. Yield: 14.72 g, 42%. Purity: 98.9 A% by HPLC (220 nm); 91.7 wt% by ^1H NMR.

^1H NMR (DMSO- d_6 , 500 MHz) δ 8.37 (brs, 2H), 7.59 (d, $J = 6.60$ Hz, 1H), 6.78 (s, 1H), 6.40 (d, $J = 6.55$ Hz, 1H), 3.40 (s, 3H).

MS (ES) $m/z = 154$ $[\text{M}+\text{H}]^+$.

A second batch of product is collected by reducing the volume of the filtrate under reduced pressure, adding isopropyl acetate (200 mL) at 21°C to the concentrated solution, and mixing the resultant slurry for 2 hours. The resultant solids are collected by filtration,

washed with isopropyl acetate (50 mL) and dried under reduced pressure at 21°C to provide a second crop of **1** as a white solid. Yield: 10.42 g, 28%. Purity: 98.0 A% by HPLC (220 nm); 85.6 wt% by ¹H NMR.

Total yield based on both crops of **1**: 70%.

5


Example 2

Synthesis of (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one monohydrate (**2**)

Compound **2** is prepared using the procedure depicted in Scheme 4 and described below.

10

Scheme 4



15 A reaction flask is charged with (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one (19.66 g, 45.47 mmol) (see Ex. 588 of WO/2009/017664), compound **1** (7.65 g, 50.02 mmol), [1,1'-bis(diphenylphosphino)ferrrocene]dichloropalladium(II), complex with dichloromethane (37.40 mg, 0.046 mmol), potassium carbonate (18.85 g, 136.42 mmol) and 2-propanol (100 mL). The flask is evacuated and refilled with argon three times. The contents of the reactor are heated to 80°C and held for about 6 hours at which time compound **1** is completely consumed. The contents of the reactor are then treated with a solution of N-acetyl-L-cysteine (0.75 g, 4.58 mmol) in 2-propanol (100 mL) and stirred at 80°C for 2 hours. The resultant suspension is then filtered. (The suspension is maintained at 50°C to 25 70°C during the filtration step.) The resultant solids are then rinsed with 2-propanol (50 mL pre-heated to 70°C). The combined filtrate and washes is heated to 70°C, maintained at reduced pressure until about 150 ml of volatiles are removed, cooled to 65°C, and

seeded with compound **2**. The resultant suspension is stirred at 60 - 65°C for 0.5 hours, cooled to 0°C over about 2 hours, and maintained at 0°C for 1 hour. The resultant solids are collected by filtration and washed with cold 2-propanol (50 mL). The solids are then recrystallized from a mixture of 2-propanol (40 mL) and water (200 mL) to provide


5 compound **2** (monohydrate) as a white solid. Yield: 19.38 g, 88.2 % yield based on BII135541. Purity: 98.96 wt%. Analysis of the product agrees with the data reported in Example 48, Method 2 of WO/2009/134400 which describes the synthesis of the monohydrate of compound **1** by reacting 4-iodo-1-methylpyridin-2(1H)-one with (S)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-

10 yl)phenyl)ethyl)-1,3-oxazinan-2-one.

Claims


What is claimed is:

- 5 1. A compound of formula (I):



wherein:

- 10 n is 0, 1, 2 or 3;
 R¹ is -(C₁-C₆)alkyl or -(C₃-C₆)cycloalkyl; wherein said -(C₁-C₆)alkyl and -(C₃-C₆)cycloalkyl may be optionally be substituted with one to three groups independently selected from -(C₁-C₆)alkyl, -O(C₁-C₆)alkyl, halo, -NH₂, -NH(C₁-C₆)alkyl, -N((C₁-C₆)alkyl)₂, and -CN; and
- 15 each R² is independently selected from -(C₁-C₆)alkyl, -O(C₁-C₆)alkyl, -(C₃-C₆)cycloalkyl, halo, -NH₂, -NH(C₁-C₆)alkyl, -N((C₁-C₆)alkyl)₂, and -CN.
2. The compound of claim 1, wherein R¹ is -(C₁-C₆)alkyl.
3. The compound of claim 1 or 2, wherein R¹ is methyl.
4. The compound of claim 1, wherein R¹ is -(C₃-C₆)cycloalkyl.
- 20 5. The compound of claim 1 or 4, wherein R¹ is cyclopropyl.
6. The compound of any of claims 1-5, wherein n is 0.
7. The compound of claim 1, wherein R¹ is methyl and n is 0.
8. The compound of claim 1, wherein R¹ is cyclopropyl and n is 0.
9. A method of making the compound of formula (I) of claim 1, comprising allowing
- 25 compound of formula (II)




to react with a Grignard reagent of formula R^3MgX to form a first intermediate;

allowing the first intermediate to react with an alkylborate of formula $B(OR^4)_3$ to form a second intermediate; and


- 5 hydrolyzing the second intermediate to form the compound of formula (I); wherein R^1 , R^2 and n are as defined above for the compound of formula (I); R^3 and R^4 are each independently a $-(C_1-C_6)$ alkyl; L is a leaving group selected from halo and trifluoromethanesulfonyloxy; and X is a chloro, bromo, or iodo.

- 10 10. A method of making a compound of formula (IV), or a hydrate thereof:




the method comprising:

allowing a compound of formula (I):



15

to react with a compound of formula (III):



(III)

wherein:

ring A in the compound of formula (III) is a C₆₋₁₀ aryl or 5 to 11-membered heteroaryl;

5 L is a leaving group;

n is 0, 1, 2 or 3;

R¹ is -(C₁-C₆)alkyl or -(C₃-C₆)cycloalkyl; wherein said -(C₁-C₆)alkyl and -(C₃-C₆)cycloalkyl may be optionally be substituted with one to three groups independently selected from -(C₁-C₆)alkyl, -O(C₁-C₆)alkyl, halo, -NH₂, -NH(C₁-C₆)alkyl, -N((C₁-

10 C₆)alkyl)₂, and -CN; and

each R² is independently selected from -(C₁-C₆)alkyl, -O(C₁-C₆)alkyl, -(C₃-C₆)cycloalkyl, halo, -NH₂, -NH(C₁-C₆)alkyl, -N((C₁-C₆)alkyl)₂, and -CN.

11. The method of claim 10, wherein:

15 the compound of formula (I) is 1-methyl-2-oxo-1,2-dihydropyridin-4-ylboronic acid;

the compound of formula (III) is (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one; and

20 the compound of formula (IV) is (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one, or a hydrate thereof.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2011/037525

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07F5/02
ADD.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
C07F
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, BIOSIS, CHEM ABS Data, COMPENDEX, EMBASE, INSPEC, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2006/017443 A2 (OSI PHARM INC [US]; AHMED SALEH [GB]; BARBA OSCAR [GB]; BLOXHAM JASON) 16 February 2006 (2006-02-16) example 77	1-10
X,P	WO 2010/104830 A1 (SQUIBB BRISTOL MYERS CO [US]; AHMAD SALEEM [US]; WASHBURN WILLIAM N [U]) 16 September 2010 (2010-09-16) pages 96-97	1-10
A,P	WO 2011/031979 A1 (CYLENE PHARMACEUTICALS INC [US]; HADDACH MUSTAPHA [US]; RYCKMAN DAVID) 17 March 2011 (2011-03-17)	1-10

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search 24 August 2011	Date of mailing of the international search report 05/09/2011
--	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Bareyt, Sébastien
--	--

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2011/037525

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2006017443	A2	16-02-2006	AR 050365 A1 18-10-2006
			BR PI0514094 A 27-05-2008
			CA 2575808 A1 16-02-2006
			EP 1797054 A2 20-06-2007
			JP 2008508358 A 21-03-2008

WO 2010104830	A1	16-09-2010	NONE

WO 2011031979	A1	17-03-2011	US 2011071115 A1 24-03-2011
